Post on 01-Feb-2020
European situation on drugs and perspectives for next 10-15 years
Nasjonal Fagkonferanse for lavterskeltiltak i rusfeltet
OSLO 29-11-2017
Julian Vicente (EMCDDA)
Approach used
2
Look at the situation in 2017 (16-15) such as it was presented in EDR
Project drug by drug (some drugs/groups of drugs) foreseeable situation in 10-15 years and general drivers
If there are not major unexpected changes, the projection can be correct and we can consider this as the central scenario
But unexcepted changes are common on drugs situation; some included
Finally speculation on substantial changes (but still plausible)
Method to project central scenarios in 10-15 years
3
Developments in some EU countries and other regions (e.g. USA, opioids), Trendpotter results and models of past emerging trends (e.g. ecstasy)
Developments often progressive from local trends, but could be quick (e.g. NPS if positive experience and not very toxis)
Developments accelerated by rapid diffusion channels (internet) and rapid market developments (globalization)
Classical monitoring tools should be adapted to new scenario
Diversification of European regions more complex picture
Some relevant trends in last 10-15 years
4
Cannabis treatments greatly increased Cannabis local cultivation and high potency products Heroin and injecting declined OST increase Opioid diversified (heroin, substitution medicines, fentanyls…) Aging drug users Stimulants markets and use very diversified Decline in HIV and Hep C in the spotlight Increase in overdose deaths in last years New online markets and cryptomarkers for supply NPS emerged; cathinones, cannabinoids, synthetic opioids
Big country variations
Some drivers for next years; already started
5
• Policy and politics; cannabis in the Americas with different models
• New technologies (production, distribution and marketing)
• Increases in cultivation (poppies, coca, marihuana)
• Globalization of the markets (e.g. NPS from China, darknet…)
• Supply reduction strategies (e.g. MDMA, heroin drought)
• Social and cultural/fashion trends
• Demographics – aging users – new groups of users
• Polydrug use
• Improvement in responses (OST, NSP, Low threshold, THN)
More diverse and complex markets (products, users, technology)
Opioids
High-risk opioid users: heroin still dominates
7
1.3 million high-risk opioid users
An ageing cohort
Overdose deaths: rise for third year
8 440 deaths in 2015 Heroin and other opioids a
concern Increases among almost all age groups
8
630 000 receive opioid substitution treatment methadone most common OST medication national OST trends and coverage varies
1.4 million people in treatment (delete)
9
Opioids: possible developments in 10-15 years
10
New populations at risk of use Medical users of opioids heroin (USA) –unlikely such extension New marginalised populations (long-term unemployment, social young
subcultures, some immigrants groups vulnerable)
Supply side Increased supply of cheap heroin. Increased supply of synthetic opioids (real threat: e.g. fentanyls-)
Possible positive factors Success/increase in OST Continue general high perception of risk Decrease in supply (enforcement or geo-political factors)
Opioids: possible developments in 10-15 years
11
Risk behaviour leading to harms Injecting decreasing, but polydrug use and aging an issue
Overdose deaths Decreases with low injection and broad access to OST New approaches increasing (THN, Safe Consu. Facilities) But in some countries increases continue (polydrug use, leaking of
OST, new potent opioids
Infectious diseases HIV decreasing in almost all EU countries –local outbreaks? HCV high in most countries – combination of harm reduction and new
treatments (very expensive) can decrease prevalence
Figura 8. Proporción de tratados por primera vez en la vida por abuso o dependencia de heroína, cuya vía principal de administración era parenteral. España (%), 1991-2002.
FUENTE: DGPNSD. Observatorio Español sobre Drogas (OED). Indicador Tratamiento.
1993
1995
1991
1997
<20% 20-39% 40-60% >60%
1999
2002
Stimulants
Cocaine: increases in wastewater analysis
Cocaine residues in 22/33 cities between 2015–2016
14
MDMA market: recovery continues
High-strength products available Large-scale production facilities
dismantled (BE and NL) seizures increasing
15
Amphetamines market
16
Amphetamine — overall stability
Methamphetamine — seizures are 1/6 of all amphetamines seizures, but overall increasing trends 2002-2015
Amphetamines: use and problems
17 More used in the North
… rising treatment demand
Stimulants: Possible developments in 10-15 years
18
Cocaine: Increasing again (supply and use) Powder cocaine: big extension to all Europe? Not very lkely Crack concentrated in UK; why does not spread to other countries? Possible substitution treatment??
Amphetamines/Methamphetamines Often hard to distinguish by users. Popular in central and northern Europe. Big increase in methamphetamine supply indicators + increase in
treatment demand for Amph/Methamp (mainly Germany). Indications of methamphetamine spread / potential switch to smoking? Possible substitution treatment??
Stimulants: Possible developments in 10
19
Ecstasy Big decrease in availability 2008-2010 but recovering Use high in nightlife settings. Not high in general population Increase in availability, may spread use into general population? High potency presentations NL, increased risk – spread?
New synthetic stimulants In recent years; many new synthetic stimulants. Often following decreases in availability of classicals. But methedrone… Initially in recreational users, but now also in high-risk users and injection Probable further expansion of both recreational and high-risk users
Cannabis
Americas – some regulatory changes Europe – diverse
approaches to cannabis regulation and use No government currently
supporting legalisation Need to monitor and
evaluate health implications
Global cannabis policy developments
21
Cannabis: Europe’s most commonly used drug
22
88 million (>25%) adults 15–64 years have tried cannabis Almost 1% of adults
daily users National diversity in
prevalence and trends
Increasing new treatment demand — 45% of new entrants
Treatment demand for cannabis problems
23
Cannabis market
24
Over one million seizures Cannabis >70% of EU seizures Around ¾ of drug possession offences
Cannabis: Possible developments in 10-15 years
25
A major issue would be changes in regulations/laws – likely in some EU countries
Prevalence of use (young males) moderate increasing trend in many countries
Local production (herb), diversified ways of using, and emergence of synthetic analogues suggest increases in use in next years.
Continuous increase of cannabis treatment; likely to continue Services will need to increasing; treatment entries suggest that
regular/intensive users starting some years ago need to seek treatment
A certain share of present daily users (+/- 3M) will need treatment in next years - 1 M at risk – 650.000 arrested - 60.000 treatments
Cannabis: Possible developments in 10-15 year
26
Possibly CUD and social/health problems will increase, often related to polydrug use (e.g. alcohol)
Individually cannabis problems are far less intense that opioids or cocaine, but the big numbers may imply a not negligible social/health burden
Selective prevention and short interventions would need to increase
Will need regulations (driving limits…) and arresting users do not seem the way
New drugs
28
66 new substances detected in 2016 Decline from 2014 peak Impact of regulation in EU and
China? 620+ substances monitored
by EWS Deaths and acute
intoxications still a problem
NPS: drop in new detections but availability still high
Increase in seizures of synthetic cannabinoids and cathinones
29
80 000 seizures in 2015 60% of seizures are synthetic cathinones and cannabinoids
30
25 new synthetic opioids detected between 2009 and 2016
Highly potent, also found in other products
Intoxication risk to users and accidentally exposed
New synthetic opioids — a growing health threat
31
Low use in general population but problems for some groups
cathinone injection by opioid
users, MSM synthetic cannabinoids among
homeless use in prison a growing concern New report published: High-risk drug use and new psychoactive substances
NPS: high-risk use in marginalised populations
New drugs: possible developments in 10-15 years
32
Developments in chemistry, markets and communication facilitate creation/diffusion of new substances, taking advantage of legal gaps
An big number of NPS have entered market in last years. This trend kely to continue in next years, although developments of individual substances is difficult to foreseen
At present the overall public health impact seems limited, mainly due to low prevalence or decrease availability following legal control
But they are/will be potential threats to be followed closely. The epidemiological monitoring is limited; should be improved
These substances may spread using new market technologies (e.g. internet)
New drugs: possible developments in 10-15 years
33
Spread among users of other drugs – some manage to reach non using people (e.g. methedrone, synthetic cannabinoids)
Spread in population of heavy users, adding risks
NPS similar to legal medicines (e.g. benzos, pharma opioids) sold in internet may diffuse mainstream public and markets
Some NPS have more toxicity that original (e.g. synthetic cannabinoids)
Some NPS are extremely toxic (new fentanyls) and their spread could be quick and difficult to predict (EWS aim to help) USA
Possible developments in future (not a clear timeframe but plausible)
34
• Catastrophic development
• Changes in paradigms
• Change in research orientation and priorities
Catastrophic development
35
• Already happening in USA; declared a national
emergency due to opioid crisis
• Currently 50.000 – 60.000 overdose deaths per year, mainly opioids (heroin and fentanyls)
• For total population the rate is 4 times the EU (it will mean to pass for 8.000 to 36.000 deaths in 2-4 years
36
Changes in paradigms (qualitative
37
• Drug users as full citizens – participation on policy developments and decision making (e,g, Aids history)
• “Not to send the wrong message” - wrong... for who?
• Changes in legal situation on cannabis in many EU countries • It will create different needs, problems and benefits - closer to alcohol • It will be necessary ad-hoc monitoring, prevention, short interventions,
treatment • Change in many regulations and services –law enforcement- (650K
Ca)
• “high-risk drug use” will not disappear; “Normalization” as a chronic condition, without moral judgements
Changes in paradigm (quantitative)
38
• integrated low threshold centers with social service + user’s room + OST + THN + drug testing (recreational drugs and opioids)
• Broad expansion of improved treatment (OST) and quality
• Broad THN including police and pharmacies (EU negotiation of prices)
• Testing places for users and small dealers to know what they are selling
• On line resources for users
• Negotiation of prices and scalation HCV treatment
• Focus on mental health and social vulnerability since school – indicated prevention. Coordination of services (soc-edu-health-police)
• Among high-risk users; diagnosis and treatment mental health problems and social exclusion. With community services (soc-edu-health-police).
Change in research orientation and priorities
39
• Research on treatments (e.g. an synthetic opioid that gives a high but not respiratory depression). Synthetic endorphins ?? Others? Genetics?
• Promote research on properties of illegal drugs (research has been almost impossible for decades and still now is extremely difficult)
• Medical uses of individual molecules in cannabis (results promising) • Ketamine as antidepressant (in advance stage) and for alcohol dependence
(and maybe drugs) • Hallucinogens (LSD and psilocybin) for psychotherapy, depression,
dependence, death and dying • Microdosis LSD • Mindfulness • :Research in 60s/70s nothing from the 80s worldwide until recently (with probl) • Many promising substances in 60s/70s schedule I
Change in research orientation and priorities
40
• Research on treatments (e.g. an synthetic opioid that gives a high but not respiratory depression). Synthetic endorphins ?? Other sesearch
• Promote research on properties of illegal drugs (research has been almost impossible for decades and still now is extremely difficult)
• Medical uses of individual molecules in cannabis (results promising) • Ketamine as antidepressant (in advance stage) and for alcohol dependence
(and maybe drugs) • Hallucinogens (LSD and psilocybin) for psychotherapy, depression,
dependence, death and dying • Microdosis LSD • Mindfulness • :Research in 60s/70s nothing from the 80s worldwide until recently (with probl) • Many promising substances in 60s/70s schedule I
Conclusions
41
• Forecast in drug use, problems and treatment is very difficult
• Classical drugs will remain, with possible increases in amount and potency
• NPS will be continue to be a problem, depending on potency, risk, acceptability of users, regulations. Fentanyls (old or new) very risky.
• New methods of production, trafficking and marketing. Globalization • ,
• Responses will need scalation (OST and others, NSP, THN, HCV..)
• Possibly legal and regulatorily changes will take place – a basic issue will be recognizing users as full citizens with rights and obligations
emcdda.europa.eu
twitter.com/emcdda
facebook.com/emcdda
flickr.com/photos/emcdda
youtube.com/emcddatube
Julian Vicente julian.vicente@emcdda.Europa,eu
Acknowledgement: Jane Mounteney
Thank you!